You just read:

Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations

News provided by

Blueprint Medicines Corporation

May 16, 2019, 09:00 ET